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ReviewFatigue is often described by patients as a lack of energy,mental or physical tiredness, diminished endurance, and
prolonged recovery after physical activity. Etiologic mechanisms underlying fatigue are not well understood;
however, fatigue is a hallmark symptom of mitochondrial disease, making mitochondrial dysfunction a putative
biological mechanism for fatigue. Therefore, this review examined studies that investigated the association of
markers of mitochondrial dysfunction with fatigue and proposes possible research directions to enhance
understanding of the role of mitochondrial dysfunction in fatigue. A thorough search using PubMed, Scopus,
Web of Science, and Embase databases returned 1220 articles. After the application of inclusion and exclusion
criteria, a total of 25 articles meeting eligibility criteria were selected for full review. Dysfunctions in the
mitochondrial structure,mitochondrial function (mitochondrial enzymes and oxidative/nitrosative stress),mito-
chondrial energy metabolism (ATP production and fatty acidmetabolism), immune response, and genetics were
investigated as potential contributors to fatigue. Carnitine was the most investigated mitochondrial function
marker. Dysfunctional levels were reported in all the studies investigating carnitine; however, the speciﬁc type
of carnitine that was dysfunctional varied. Genetic proﬁles were the second most studied mitochondrial param-
eter. Six common pathways were proposed: metabolism, energy production, protein transport, mitochondrial
morphology, central nervous systemdysfunction andpost-viral infection. CoenzymeQ10was themost common-
ly investigated mitochondrial enzyme. Low levels of Coenzyme Q10 were consistently associated with fatigue.
Potential targets for further investigation were identiﬁed as well as gaps in the current literature.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Mitochondria are increasingly recognized as major contributors to
human health and disease because of their location and inﬂuence [7].
Mitochondria have an essential role in energy production through the
process of oxidative phosphorylation where nutrients are converted
into adenosine triphosphate (ATP), which powers many of the cells'
activities. In addition to energy production, mitochondria have been
implicated in various physiologic processes including the production
of reactive oxygen species (ROS), pyrimidine and lipid biosynthesis,
regulation of cellular levels of substrates (amino acids, metabolites, en-
zyme cofactors), apoptosis, metal (Fe–S cluster and heme) metabolism,
calcium homeostasis and ﬂux, neurotransmitter synthesis, heat produc-
tion, and insulin secretion [8,26,27]. Therefore, damage tomitochondria
can have widespread consequences [8].
Health conditions such as cancer, diabetes, ﬁbromyalgia, and serious
mental disorders such as schizophrenia and bipolar disease are also pro-
posed to result from mitochondrial dysfunction, though the links are
less clear [27,34]. Mechanisms underlyingmitochondria-related disease
states have predominantly focused onDNAdamage andROS generation
[7,27]. Mitochondrial dysfunction can be of primary (inherent) or
secondary (acquired dysfunction) origin [7,32]. Primary dysfunction
results from mitochondrial DNA (mtDNA) mutations inherited from
mothers, who are the sole contributors of mitochondria to their off-
spring [7]. Mitochondrial DNA has a much higher mutation rate than
nuclear DNA because it lacks protective histones [32], is readily exposed
to damage from ROS production [1,27,34], and lacks certain DNA repair
mechanisms [7]. Secondary mitochondrial dysfunction results from the
inﬂuence of external mechanisms such as environmental or pharmaco-
logic toxins that can damage the mtDNA [7]. Mitochondria can protect
themselves from the accumulation of damage through various quality
control mechanisms (e.g., ﬁssion and fusion) [26,43]; however, if
these mechanisms are altered, mitochondrial dysfunction can lead to
disease [4,8]. Past research has predominantly focused on the role ofmi-
tochondrial dysfunction on disease pathology. However, some studies
have investigated how mitochondrial dysfunction is associated with
the development of distressing symptoms such as fatigue, neuropathic
pain, weakness, and depression [27]; however, these investigations
are still in their infancy. This paper reviewed studies that investigated
the association of mitochondrial dysfunction with fatigue.
Fatigue is a hallmark symptom of mitochondrial disease. Fatigue is
often described by patients as a lack of energy, mental or physical tired-
ness, diminished endurance, and the need for a prolonged recovery
after physical activity [35]. Fatigue is reported by patients to be
unrelieved by rest [16,35]. As pervasive and debilitating as fatigue is,
the etiology of fatigue remains poorly understood. Without a known
pathophysiologicalmechanism for fatigue, there is aminimal consisten-
cy in its clinical deﬁnition [1,11,16,39]. Furthermore, the lack of a proper
clinical deﬁnition of fatigue contributes to its underdiagnosis and poor
management, which in turn contributes to increased symptom burden
and poorer quality of life in patients with fatigue [44]. The purpose of
this systematic review was to examine markers of mitochondrial func-
tion (in adults) that have evidence of an association with fatigue in
order to identify areas needed for further research. In this paper
markers of mitochondrial function that associate with fatigue in adult
patients were reviewed in order to describe empirical evidence of a re-
lationship between mitochondrial dysfunction and fatigue and to pro-
pose possible research directions that would enhance understanding
of the role of mitochondrial dysfunction in fatigue.2. Methods
An initial literature query was conducted in the following four
reference databases using search strategies as summarized in Table 1.
The initial search resulted in 2055 articles. After removing dupli-
cates, the abstracts of 1220 articles were assessed for relevance to the
area of interest. Abstracts that discussed the association of markers of
mitochondrial function and fatigue were selected to be included in
this review. In addition, studies were excluded if they were more than
20 years old, were not original research, were animal or cell-based
studies, investigated the effect of medication or treatment on fatigue,
mitochondrial markers or both, or measured induced fatigue through
the use of exercise or electric stimulation. Also excluded were letters,
literature reviews, notes, conference or meeting abstracts, book
chapters, editorials, dissertations, case reports or series, short reports,
workshop reports, and practice guidelines. A total of 54 articles were
selected for full-text review. Of these, 25 were excluded based upon
the aforementioned criteria, 3 were excluded because they focused on
neuroimaging, and 1 was excluded because it included children. A
total of 25 articles were selected for full review.
3. Results
Twelve of the 25 articles (48%) were published within the last ﬁve
years. Twenty-two (88%) of the studies used a cross-sectional design;
three used a repeated-measures design. Eighteen studies investigated
only patients with chronic fatigue syndrome (CFS); remaining studies
investigated a combination of myalgic encephalomyelitis (ME) and
CFS (n= 2), ME (n= 1), multiple sclerosis (n= 1), HIV-related fatigue
(HRF) (n = 1), systemic lupus erythematosus (SLE) (n = 1), and
cancer-related fatigue (CRF) (n = 1). One study restricted participant
gender and included only males [15]. A complete description of study
attributes are found in Tables 2 and 3.
CFS patients were the most studied (72% of all articles reviewed).
CFS subjects were phenotyped by clinical diagnosis using the 1988 or
1994 Center for Disease Control (CDC) diagnostic criteria alone (n =
17) or in combination with other developed criteria (n = 3), such as
the Australian deﬁnition for CFS (n = 1), the British deﬁnition for
CFS (n = 1), and the International Consensus Criteria for Myalgic En-
cephalomyelitis (ICCME) (n = 1). Two studies used other diagnostic
guidelines; one used the Oxford Consensus criteria and one group
used the diagnostic criteria established by the Royal Australasian Col-
lege of Physicians Working Group.
Fatigue was deﬁned through either clinical diagnosis alone or in
combination with self-report questionnaires. Most articles (n = 16)
quantiﬁed fatigue using a variety of questionnaires such as the Fatigue
Severity Scale (n=4), CFS Impairment Index (CFS-II) (n=2), Checklist
Individual Strength (CIS) fatigue subscale (n= 2), Sickness Impact Pro-
ﬁle (n=2), Chalder Fatigue Scale (n=1), the Fibromyalgia and the CFS
Rating Scale (FF Scale) (n = 2), Symptom Checklist 90-R (n = 2), CFS
Ability Scale (n= 2), the revised Piper Fatigue Scale (n= 2), Visual An-
alogue Scale-fatigue (VAS) (n=1), the Proﬁle of Fatigue (ProF) (n=1),
and structured interviews (n = 3).
A number of mitochondrial parameters were investigated as poten-
tial markers for the fatigue conditions. In about 70% (n = 18) of the
studies, mitochondrial biomarkers were obtained from peripheral
blood samples; in the remaining 7 studies, lower extremity skeletal
muscle biopsy specimenswere used. Dysfunctions in themitochondrial
structure, mitochondrial function, mitochondrial energy metabolism,
Table 1
Search criteria.
Database Search terms Filters Yield
PubMed Mitochondria OR mitochondrial AND fatigue Humans
English
N = 358
Scopus (TITLE (mitochondria OR mitochondrial) AND TITLE (fatigue))
(TITLE (mitochondria OR mitochondrial) AND TITLE (fatigue))
English N = 519
Web of Science Topic = (mitochondria OR mitochondrial) AND Topic = (fatigue) English N = 624
Embase ‘Fatigue’/exp AND (‘mitochondrion’/exp OR ‘mitochondrial respiration’/exp OR ‘mitophagy’/exp OR ‘mitochondrial
dna’/exp OR ‘disorders of mitochondrial functions’/exp OR ‘mitochondrial dynamics’/exp OR ‘mitochondrial energy
transfer’/exp OR ‘mitochondrial enzyme’/exp OR ‘mitochondrial gene’/exp OR ‘mitochondrial genome’/exp OR
‘mitochondrial membrane potential’/exp OR ‘mitochondrial protein’/exp OR ‘mitochondrion swelling’/exp)
Humans
English
N = 554
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potential contributors to fatigue. Studies are grouped into these four
areas for review.
3.1. Mitochondrial structure
Four studies investigated the association of fatigue with mitochon-
drial number, size, and/or shape. All four studies were cross-sectional
in design, included patients with CFS, and used muscle biopsy speci-
mens to determine the potential mitochondrial markers. One study
quantiﬁed fatigue through the use of a self-report questionnaire;
whereas, three studies assumed fatigue through medical diagnosis. In
one study about 7% of tibialis anterior (n = 69), quadriceps (n = 4),
or medial head gastrocnemius (n = 1) muscle biopsies from CFS sub-
jects had mitochondrial hyperplasia; however, because there were no
structural abnormalities noted, the authors concluded that mitochon-
drial structural abnormalities were not a feature of CFS [9]. Findings
were similar in another study in which no signiﬁcant mitochondrial
structural differences were found in the right leg vastus lateralis muscle
biopsies of CFS patients versus controls [29].
One study investigating the vastus lateralis muscle biopsies of CFS
subjects compared to normal controls found a signiﬁcantly larger (hy-
pertrophic) mitochondrial size and shape (3–8 times larger), often
with noticeable branching of the cristae, termed compartmentalization,
[2]. In another study of CFS patients with decreased energymetabolism,
the vastus lateralis muscle biopsy specimens, as categorized by ob-
served lactate to pyruvate production in the biopsy samples, were
found to have minor, nonspeciﬁc changes to mitochondrial shape and
structure (paracrystalline inclusions and increased numbers of pleo-
morphic mitochondria with proliferation of cristae) [3]. However, a
vastus lateralis muscle specimen from a CFS patientwith normal energy
metabolism showed abundant pleomorphic mitochondria, but these
structural changes were not observed in the vastus lateralis muscle
specimens from CFS subjects with increased energy metabolism [3].
In summary, three of these four cross-sectional studies investigated
the relationship between fatigue and mitochondrial number, shape,
and/or size and found no signiﬁcant differences with mitochondrial
shape and structure among CFS patients and controls. Only one study
observed signiﬁcant mitochondrial hypertrophy in the CFS patients
compared to healthy controls using skeletal muscle specimens.
3.2. Mitochondrial function
Eleven studies investigated the aspects ofmitochondrial function; all
were cross-sectional in design. Most studies (n = 8) focused on mito-
chondrial enzymes, while the rest (n = 3) focused on oxidative and/
or nitrosative stress. Most studies looked at CFS or ME/CFS patients,
while one study investigated fatigue in SLE patients.
3.2.1. Mitochondrial enzymes
Four studies measured mitochondrial enzymes using muscle biopsy
specimens and the remaining ones used peripheral blood specimens.Six studies only enrolled CFS patients, one included ME/CFS patients,
and the remaining study enrolled only ME patients. Almost all partici-
pants were enrolled based on their medical diagnoses, except for one
study which used a self-report questionnaire to measure fatigue. In
four studies fatigue was further assessed by structured clinical inter-
views (n = 2) and self-report questionnaires (n = 2).
A signiﬁcant reduction in citrate synthase, succinate reductase, and
cytochrome-c oxidasewas observed in the anterior tibialismuscle biop-
sy samples of CFS patients compared to healthy controls,whichwere at-
tributed to the reduction in physical activity commonly present in CFS
subjects [24]. A signiﬁcant reduction in citrate synthase in the right
quadriceps muscle biopsy samples from CFS subjects was also con-
ﬁrmed recently [37]. Citrate synthase is located in the mitochondrial
matrix and is an essential enzyme in the citric acid cycle [40]. Succinate
reductase (Complex II) and cytochrome-c oxidase (Complex IV) are two
of the four mitochondrial transmembrane enzyme complexes of the
electron transport chain [40].
In contrast, one study observed no signiﬁcant difference with the
skeletal muscle biopsies of partial cytochrome-c oxidase and
myoadenylate deaminase (MAD) between CFS patients and healthy
controls; MAD was more associated with the symptom of myalgia
than fatigue [9]. MAD is the muscle-speciﬁc subtype of adenosine
monophosphate (AMP) deaminase and is involved in nucleotidemetab-
olism [40,45]. Another study observed no difference in the vastus
lateralis muscle biopsy levels of lactate dehydrogenase and
cytochrome-c oxidase activity in CFS patients and controls [3]. Lactate
dehydrogenase is an enzyme located in the cytoplasm of cells and
contributes to the formation of lactate from pyruvate [40].
Four articles examined the levels of Coenzyme Q10 (CoQ10) in
fatigued patients with either ME or CFS compared to healthy controls
[19,20,22,23]. ME and CFS patients had signiﬁcantly lower plasma levels
of CoQ10 compared to healthy controls [19,20]. Plasma CoQ10 was also
observed to be signiﬁcantly lower in ME/CFS and depressed patients
with CFS compared to controls [22,23]. Signiﬁcant, inverse relationships
were observed with plasma CoQ10 levels and severity of illness scores
of ME/CFS patients, speciﬁcally, greater fatigue and autonomic
symptoms were associated with lower levels of CoQ10 [22]. However,
in patients with depression there was no correlation observed with se-
verity of illness total or individual scores and plasma CoQ10 levels [23].
The presence of CFS independently predicted low plasma CoQ10 levels
[19,20,23].
No longitudinal studies investigated the association between mito-
chondrial enzymes and fatigue. The cross-sectional studies reviewed
reported conﬂicting associations between mitochondrial enzymes and
fatigue. CoQ10 was the most studied mitochondrial enzyme, where re-
duced plasma levels of CoQ10 were found in the fatigued populations
compared to healthy controls.3.2.2. Oxidative/nitrosative stress
Three cross-sectional studies, two from the same research group, in-
vestigated oxidative and nitrosative stress in CFS and ME patients com-
pared to healthy controls. All three used peripheral blood specimens for
Table 2
Studies investigating mitochondrial dysfunction in CFS and/or ME.
Authors Study design Sample characteristics Fatigue deﬁnition Fatigue measurement Mitochondrial marker assessed Sample source Association to fatigue
Edwards et al. [9]. Cross-sectional,
descriptive
n = 74 CFS patients
Controls:
a. n = 34 patients with myalgia
b. n = 22 asymptomatic con-
trols
Not speciﬁed CFS diagnosis (criteria/
guidelines not speciﬁed)
1. Mitochondrial hyperplasia
2. Cytochrome c oxidase
3. Myoadenylate deaminase
Muscle biopsy from either:
a. Tibialis anterior
b. Quadriceps
c. Gastrocne-mius, medial head
No signiﬁcant differences between CFS
patients and controls.
Kuratsune et al.
[18].
Cross-sectional,
descriptive
n = 38 CFS patients
Controls:
n = 308 healthy volunteers
CDC 1988 criteria CFS diagnosis according to
CDC criteria
1. Free L-carnitine
2. Acylcarnitine
Serum Free L-carnitine levels lower in male
CFS patients and higher in female CFS
compared to controls; however, not
statistically signiﬁcant.
Acylcarnitine levels lower (p b .001) in
CFS patients compared to controls.
In CFS patients, lower acylcarnitine
levels associated with worse perfor-
mance and increased symptom burden
at initial exam. Upon symptom
improvement, acylcarnitine levels
increased (p b .02).
Behan et al. [2]. Cross-sectional,
descriptive
n = 31 CFS patients
Controls:
n = 20 volunteers with no mus-
cle disease
CDC 1988 criteria CFS diagnosis according to
CDC criteria
1. Histological
2. Histochemical
3. Ultrastructural
Vastus lateralis muscle biopsy Size and morphology of mitochondria
showed differences between CFS and
controls. No statistical data provided.
Plioplys and
Plioplys [29].
Cross-sectional n = 15 CFS patients
Controls:
n = 15; age and sex-matched
healthy volunteers
1. CDC 1988 &
1994 criteria
2. British &
Australian deﬁni-
tions for CFS
1. Fatigue Severity Scale
(FSS)
2. Beck Depression
Inventory (BDI)
3. Symptom Checklist 90-R
4. CFS Impairment Index
(CFS-II).
5. Structural Clinical
Interview for theDSMIII-R-
Nonpatient Edition
Ultrastructural exam of
mitochondria
Right vastus lateralis muscle biopsy No signiﬁcant differences upon
structural exam between CFS patients
and controls.
Carnitine levels Serum Negative association between
acylcarnitine levels and CFS-II mental
index score (r = −0.761, p b 0.01)
and total score (r = −0.634,
p b 0.05).
Plioplys and
Plioplys [30].
Cross-sectional n = 35 CFS patients
Controls:
a. Mayo clinic normative data
(n = 85)
b. Historical study ([18].)
CDC 1988 criteria 1. FSS
2. BDI
3. Symptom Checklist
90-R
4. CFS-II.
Carnitine levels: total, free,
aceylcarnitine
Serum Total carnitine lower in female
(p b .001) and male (p b .05) CFS
patients compared to Mayo clinic data.
Free carnitine lower in female (p b .01)
and male (p b .05) CFS patients
compared to Mayo clinic data.
Acylcarnitine lower in CFS patients
compared to historical study controls
(p b .00001).
Free carnitine lower in CFS patients
compared to historical controls
(p b .00001).
Total carnitine lower in CFS patients
compared to historical controls
(p b .00001).
Free carnitine correlated with CFS-II
physical impairment subset (r = .412,
p b .05).
Negative correlation between FSS and
free carnitine (r = −.496, p = .02),
and total carnitine and FSS
(r = −.473, p = .02).
McArdle et al.
[24].
Cross-sectional n = 54 CFS patients only in-
cluded n = 34 for viral analysis
Controls:
a. For enzyme comparison
n = 16 from a previous study
b. For RNA detection n = 10
1. Diagnosis with
CFS on the basis of
complaints of
muscle pain and
fatigue
2. Diagnosis
Not mentioned 1. Mitochondrial enzymes:
a. Citrate synthase
b. Succinate reductase
c. Cytochrome-c oxidase
Anterior tibialis muscle biopsy Reduction in all 3 mitochondrial
enzyme activities (p b .05) in CFS
patients compared to control values
from a previous study.
2. Presence of enteroviral RNA Failed to detect evidence of enteroviral
RNA.
(continued on next page)
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Table 2 (continued)
Authors Study design Sample characteristics Fatigue deﬁnition Fatigue measurement Mitochondrial marker assessed Sample source Association to fatigue
patients undergoing orthopedic
surgery; no muscle damage or
fatigue.
conformed to the
Oxford Consensus
Criteria
Behan et al. [3]. Cross-sectional n = 16 CFS patients
Controls:
n = 10 healthy volunteers
CDC 1994 criteria. CFS diagnosis according to
CDC criteria
1. Aerobic capacity
a. Pyruvate
b. Lactate
c. L/P ratio
d. Respiratory capacity
e. Cytochrome-c oxidase
f. LDH
2. DNA analysis
a. Total mtDNA volume
b. mtDNA rearrangements
c. Point mutation at nucleotide
pair 3243
d. Two deletions: mtDNA 4977
mtDNA 7436
3. Histological, Histochemical, and
Ultrastructural examination
Right or left vastus lateralis muscle
biopsy
Increased pyruvate levels in CFS
patients (p = .053).
All other biological parameters
showed no signiﬁcant ﬁndings
between the groups.
Soetekouw et al.
[38].
Cross-sectional n = 25 Caucasian, female CFS
patients
Controls:
n = 25 age- and sex-matched
healthy volunteers
1. CDC 1994
criteria.
2. Fatigue with
substantial ADL
impairment:
a. A score of 35+
on the Checklist
Individual
Strength subjec-
tive fatigue sub-
scale
b. a score of 750+
on the weighted
total score of the
Sickness Impact
Proﬁle.
1. Checklist Individual
Strength (CIS)
2. Sickness Impact Proﬁle
(SIP)
1. Carnitine levels: total, free, &
acylcarnitine
2. Carnitine ester proﬁles
Serum CFS patients were more fatigued
(p b .001) and had more functional
impairment (p b .001) as determined
by questionnaires.
No signiﬁcant differences with any of
the biologic markers between the
groups.
Kurup and Kurup
[20].
Cross-sectional n = 15 CFS patients
Controls:
n = 45 age and sex-matched
healthy volunteers
CDC criteria Structured clinical
interview to assess CFS
and comorbid conditions
Mitochondrial markers:
1. Ubiquinone
2. ROS/RNS
a. MDA
b. Hydroperoxide
c. Conjugated dienes
d. NO
3. Antioxidants
a. Glutathione
b. SD
c. Catalase
d. GSH peroxidase
e. GSH reductase
RBCs and plasma/serum 1. Ubiquinone lower in CFS patients
(F = 259.36, p b .01)
2. ROS markers higher in CFS patients
a. MDA (F = 4.56, p b 0.05)
b. Hydroperoxide (F = 3.25,
p b 0.05)
c. Conjugated dienes (F = 16.21,
p b 0.01)
d. NO (F = 6.54, p b 0.05)
3. Antioxidants lower in ME patients
a. Glutathione (F = 8.36, p b 0.05)
b. SD (F = 7.56, p b 0.05)
c. Catalase (F = 3.98, p b 0.05)
d. GSH peroxidase (F = 11.26,
p b 0.01)
e. GSH reductase (F = 4.26, p b 0.05)
Kaushik et al. [17]. Repeated measures: two
time points 6 months
apart during which
symptoms did not vary
signiﬁcantly
n = 25 CFS patients
Controls:
1. Microarray, n = 25 age- and
sex-matched normal blood do-
nors
2. Real-time PCR, n = 21 age-
and sex-matched normal blood
donors
CDC 1994 criteria. 1. Diagnosis of CFS ac-
cording to CDC criteria
2. Chalder Fatigue Scale
Real-time PCR Peripheral blood mononuclear cells
(PBMCs)
16 Genes differentially expressed in
CFS patients (15 genes up-regulated, 1
down-regulated).
3 Up-regulated genes are located in
the mitochondria:
a. EIF2B4 (p = 1.8 × 10−5)
b. EIF4G1 (p = 7.63 × 10−13)
c.MRPL23 (p = 1.25 × 10−6)
2 Up-regulated genes for peroxisomal
function, ABCD4 (p = .00190) and
PEX16 (p = .0126), suggesting en-
hanced defense to oxidative damage.
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Vernon et al. [41]. Repeated measures:
baseline, 2–3 weeks,
4–6 weeks, 3 months,
6 months (in those with
symptoms), & 12 months.
n = 5 with symptoms
suggestive of infectious
mononucleosis with provisional
lab conﬁrmation
Controls:
n = 5 controls that recovered
promptly from infectious
mononucleosis; HLA-A and -B,
sex, and age-matched.
CDC 1994 criteria 1. Diagnosis of CFS ac-
cording to CDC criteria
2. Self-report and inter-
view assessment of psy-
chological and physical
health.
Gene transcription patterns PBMCs Due to small n in each group, data was
categorized by time periods: early
(baseline-3 months) and late
(N6 months following disease onset).
Early Phase: 23 genes differentially
expressed between cases and
controls; 8 expressed in cases and
involved binding and metabolism
ontologies.
Early & Late Phase: 24 genes
signiﬁcantly different between cases
and controls; 12 genes are associated
with mitochondrial function.
Hokama et al. [13]. Cross-sectional n = 328 CFS patients
n = 18 CCFP patients
n = 8 GWVs
n = 15 PC patients
n = 49 normal, healthy
controls
CDC 1994 criteria CFS diagnosis according to
CDC criteria
1. Phospholipids
2. Anti-cardiolipin (aCL)
antibodies
Serum CFS, CCCP, GWV, and PC patients have
cardiolipin associated with mito-
chondrial membrane.
The presence of aCLwas also detected.
Hokama et al. [12]. Cross-sectional n = 40 CFS patients CDC 1994 criteria CFS diagnosis according to
CDC criteria
Anti-cardiolipin antibodies Serum IgM isotope present in 95% of CFS
patients. IgG isotype present in 10%
and the IgA isotype present in 5% of
CFS patients.
Maes et al. [23]. Cross-sectional n = 35 major depressed
patients; n = 17 patients had a
diagnosis with CFS
Controls:
n = 22 healthy volunteers
1. 1994 CDC
criteria
2. Criteria:
a. Severe chronic
fatigue for at least
6 months
b. At least 3 Addi-
tional symptoms
from a checklist
1. CFS diagnosis according
to CDC criteria
2. Fibromyalgia and CFS
Rating Scale (FF scale)
CoQ10 levels Plasma Depressed patients with CFS had
lower plasma CoQ10 than depressed
patients without CFS (F = 8.7,
df = 1/33, p = .006).
CFS independently predicted low
CoQ10 values (F = 4.3, df = 1/31,
p = .04).
Myhill et al. [25] Cross-sectional n = 71 CFS patients
Controls:
n = 53 normal, healthy volun-
teers
CDC 1994 criteria 1. CFS diagnosis according
to CDC criteria
2. CFS Ability Scale
1. “ATP Proﬁle” test:
a. ATP concentration and ATP ratio
b. The efﬁciency of ox-phos
process
c. Translocator (TL) protein
function (TL-OUT and TL-IN)
2. Mitochondrial Energy Score
(MES)
Neutrophils Patients grouped into 3 groups based
on CFS Ability Scale scores: very
severe (VS), severe (S), and moderate
(M).
For most of the 5 factors of the “ATP
Proﬁle Test” the percentage of
patients who are in the normal region
increases from VS, S, to M.
The MES is highly correlated with the
CFS Ability scale (R2 = .645,
p b .001).
Pietrangelo et al.
[28].
Cross-sectional n = 4 CFS patients
n = 2 female patients, meeting
CDC criteria n = 2 male
patientsmeeting CDC criteria for
CFS
Controls:
n = 9 healthy volunteers
CDC 1994 criteria 1. CFS diagnosis according
to CDC criteria
2. Skeletal muscle mem-
brane testing
Global transcriptome analysis aaRNA obtained from vastus
lateralis muscle biopsy
47 Genes signiﬁcantly altered in CFS
patients: 2 up-regulated, 38 down-
regulated and 7 up-regulated in
females, but down-regulated inmales.
Gene Pathways: Control of Ox-Phos; 3
mitochondrial genes were down-
regulated: SOD2, FDX1, and NQO1.
Energy Balance; depressed transcrip-
tion of several genes implicated in the
energy metabolism: PFKFB3, PDK4,
GOT1, AMPD3, and ATP-binding
cassette member 5. One gene, VLDLR
was up-regulated
Apoptosis; FOS,MYC, SOX17, AATF, and
CEBPDwere all down-regulated.
Reuter and Evans
[33].
Cross-sectional n = 44 CFS patients
Controls:
n = 49 age and gender-
matched healthy subjects
Royal Australasian
College of
Physicians CFS
clinical practice
guidelines
1. Medical diagnosis of CFS
using the Royal Austral-
asian College of Physicians
CFS clinical practice
1. Endogenous carnitine: total, L-,
and acylcarnitine
2. 35 individual carnitines
Plasma CFS patients had lower individual
carnitines: C8:1 (p = .0201), C14
(p = .0023), C16:1 (p = .0383), C18
(p = .0104), C18:1 (p b .0001), and
C18:2 (p b .0001).
(continued on next page) 17
K.Filler
etal./BBA
Clinical1
(2014)
12
–23
Table 2 (continued)
Authors Study design Sample characteristics Fatigue deﬁnition Fatigue measurement Mitochondrial marker assessed Sample source Association to fatigue
guidelines
2. FSS
CFS patients had higher C12DC
(p b .0001) and C18:1-OH
(p = .0191).
Negative correlation between FSS
scores and C8:1, C14, C16:1, speciﬁ-
cally with C18:1 (R = −.3547,
p = .0009) and C18:2 (R = -.4191,
p b .0001).
Signiﬁcant positive correlations
between fatigue severity and C12DC,
C16, and C18:1-OH.
Smits et al. [37]. Cross-sectional n = 16 CFS patients
Controls:
n = 11male healthy volunteers
1. CDC 1994
criteria
2. Severe fatigue
determined as N35
on the fatigue sub-
scale of the CIS.
3. Fatigue longer
than 6 months
4. Fatigue not
explained by
somatic or psychi-
atric illness or
ongoing exertion
and is not relieved
by rest.
5. Myalgia and/or
exercise intoler-
ance.
6. Substantial
functional impair-
ment determined
by a score of 700+
on the SIP-8.
1. Diagnosis of CFS ac-
cording to CDC criteria
2. CIS
3. SIP-8.
1. ATP production rate
2. Respiratory chain complexes
activity (Complex I, II + III, II, and
IV)
3. Citrate Synthase levels
Right quadriceps muscle biopsies No signiﬁcant differences in ATP
production or respiratory chain
complex activity in CFS patients.
Citrate synthase levels were lower in
CFS patients (p b .001).
Maes et al. [22]. Cross-sectional n = 58 ME/CFS patients
Controls:
n = 22 healthy volunteers
1994 CDC criteria 1. CFS diagnosis
2. FF scale
CoQ10 levels Plasma Plasma CoQ10 lower in ME/CFS
patients (F = 31.0, df = 1/78,
p = .00001)
Negative association between CoQ10
and total FF scale score (r = .28,
p = .03).
Negative correlation between CoQ10
and fatigue (r = −.86, p b 10−5).
Booth et al. [5]. Cross-sectional n = 61 ME/CFS patients
(Cohort 1; still ill after
interventions; from the
previous study)
n = 138 ME/CFS patients
(Cohort 2; no prior
interventions)
Controls:
n = 53 normal, healthy
volunteers [25]
1. CDC 1994
criteria
2. ICCME (most, if
not all were met)
1. CFS diagnosis according
to CDC criteria
2. The Bell CFSAbility Scale
1. 5 Parameters of the ATP Proﬁle
test:
a. ATPmg
b. ATPend
c. Ox-Phos
d. TL OUT
e. TL IN
2. MES
3. Nfn
4. MESinh
Neutrophils ME/CFS patients had reduced ATP
production
Mitochondrial dysfunction, mainly
through partial blockage of the TLwas
demonstrated in both cohorts.
It was observed that neutrophils used
at least two different pathways to
compensate for mitochondrial dys-
function.
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Table 3
Studies investigating mitochondrial dysfunction in other fatigued populations.
Authors Study design Sample characteristics Fatigue deﬁnition Fatigue measurement
technique
Mitochondrial dynamic
assessed
Sam ource Findings
Fukazawa et al. [10]. Cross-sectional n = 25 MS patients; n = 11
with disabling fatigue and
n = 14 without fatigue
Controls:
n = 25 age- and sex-matched
healthy volunteers
1. Debilitating, persistent,
or relapsing fatigue noted
after the onset of MS
2. Lack of other causes of fatigue
based on a history, physical
examination, and laboratory
tests.
Medical diagnosis of fatigue Carnitine levels: total,
free,
and acylcarnitine
Seru No signiﬁcant differences in carnitine levels
between the groups.
Kurup and Kurup
[19].
Cross-sectional n = 15 ME patients
Controls:
n = 45 age and sex-matched
healthy volunteers
CDC criteria Structured clinical interview
to assess CFS
and comorbid conditions
Mitochondrial markers:
1. Ubiquinone
2. ROS/RNS
a. MDA
b. Hydroperoxide
c. Conjugated dienes
d. NO
3. Antioxidants
a. Glutathione
b. SD
c. Catalase
d. GSH peroxidase
e. GSH reductase
RBCs plasma/
seru
1. Ubiquinone lower in ME patients
(F = 259.36, p b .01)
2. ROS markers higher in ME patients
a. MDA (F = 4.56, p b 0.05)
b. Hydroperoxide (F = 3.25, p b 0.05)
c. Conjugated dienes (F = 16.21, p b 0.01)
d. NO (F = 6.54, p b 0.05)
3. Antioxidants lower in ME patients
a. Glutathione (F = 8.36, p b 0.05)
b. SD (F = 7.56, p b 0.05)
c. catalase (F = 3.98, p b 0.05)
d. GSH peroxidase (F = 11.26, p b 0.01)
e. GSH reductase (F = 4.26, p b 0.05)
Segal et al. [36]. Cross-sectional n = 71 SLE patients
Controls:
n = 51 healthy volunteers
Not speciﬁed 1. Visual Analogue Scale-fatigue
2. FSS
3. Proﬁle of Fatigue (ProF)
F2-isoprostane Plasm SLE patients with fatigue had higher levels of
F2-isoprostane than non-fatigued SLE patients
(p = .0076).
Positive correlation between F2-isoprostane
and fatigue in SLE patients.
F2-isoprostane predicts higher FSS scores in
SLE patients (p = .0002).
Hsiao et al. [15]. Repeated measures; Baseline
Day 1, Day 7, Day 14, Day 19/
21,
Day 38–42 of EBRT, and Day
68–72 after EBRT
n = 15 men with non-
metastatic
prostate cancer receiving ADT
and scheduled to receive EBRT.
Controls:
n = 15 age, gender, and race
matched controls.
Not speciﬁed Revised Piper Fatigue Sale Radiation-induced
changes
in mitochondria-related
gene expression
WBC A Eleven genes related to mitochondrial function
were differentially expressed over time during
EBRT (p b .05).
After Bonferroni, only SLC25A23was signiﬁcantly
down-regulated post-EBRT (p = .008 - .02).
Eight of the 11 differentially expressed genes
were signiﬁcantly associated with fatigue
scores (p = .012 - .0003).
Voss et al. [42]. Cross-sectional n = 5 HIV patients with
high fatigue
n = 5 HIV patients with
low fatigue
Controls:
n = 5 healthy controls
HIV-related fatigue Revised 26-Item Piper Fatigue
Scale
Genomic (mitochondrial
and nuclear) expression
markers of mitochondrial
dysfunction
CD1 cells Genes pertaining to mitochondrial function
include:
CHD1L (τ = −.49) and ALDOB (τ = −.62),
TIMM17B (τ = .62), GSR (τ = .62), IMMT
(τ = .57), and SLC25A26 (τ = .62).
2 HIV-associated genes related to mitochondrial
function, fatty acid metabolism: ACAD9
(τ = .20)
and PPAR-alpha (τ = −.44).
CFS = chronic fatigue syndrome; ME = myalgic encephalomyelitis; CDC = Centers for Disease Control and Prevention; DSM III-R = Diagnostic & Statistical Manual of Mental Disorde rd Edition Revised RNA = ribonucleic acid; L/P ratio = lactate/
pyruvate ratio;DNA = deoxyribonucleic acid;mtDNA = mitochondrial DNA;ADLs = activities of daily living; ROS = reactive oxygen species; RNS = reactivenitrogen species;MDA = londialdehyde;NO = nitric oxide; SD = superoxidedismutase;
GSH = glutathione; RBCs = red blood cells; PCR = polymerase chain reaction; PBMCs = peripheral bloodmononuclear cells; EIF2B4 = eukaryotic translation initiation factor 2B, subun δ, tv-1; EIF4G1 = eukaryotic translation initiation factor 4γ, 1, tv-
5;MRPL23 = mitochondrial ribosomal protein L23; ABCD4 = ATP binding cassette, subfamily D (ALD), member 4, tv-4; PEX16 = peroxisomal biogenesis factor 16, tv-1; HLA = h n leukocyte antigen; CCFP = chronic ciguatera ﬁsh poisoning;
GWVs = Gulf War Veterans; PC = prostate cancer; IgM = immunoglobulin subtype M; IgG = immunoglobulin subtype G; CoQ10 = Coenzyme Q10; ATP = adenosine triphosph TL-IN = transports ATP to cytosol; TL-OUT = transports ADP
from cytosol to mitochondria; aaRNA = amino allyl RNA; Ox-Phos = oxidative phosphorylation; SOD2 = superoxide dismutase 2, mitochondrial; FDX1 = ferredoxin 1; NQO1 = nic amide adenine dinucleotide phosphate dehydrogenase quinone
1; PFKFB3 = 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3(allosteric enzyme); PDK4 = pyruvate dehydrogenase kinase, isoenzyme 4; GOT1 = glutamic-oxaloacetic transam se 1; AMPD3 = adenosine monophosphate deaminase (isoform
E); VLDLR = very low density lipoprotein receptor; FOS = V-fos FBJ murine osteosarcoma viral oncogene homolog;MYC = v-myc myelocytomatosis viral oncogene homolog; SOX1 SRY-related HMG-box transcription factor; AATF = apoptosis
antagonizing transcription factor; CEBPD = nuclear factor-IL6-beta; ICCME = International Consensus Criteria Myalgic Encephalomyelitis; ATPmg = whole cell ATP measured by addi xcess Mg; ATPend = ATP measured with endogenous Mg only;
Nfn = number of factorswith normal; values;MESinh = revisedMESusing the %ATP inhibited instead of TL IN;MS = multiple sclerosis; EBRT = external beam radiation therapy;WBC white blood cells; SLC25A23 = solute carrier family 25,member
23; HIV = human immunodeﬁciency virus; CD14 = monocyte; LDH = lactate dehydrogenase.
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20 K. Filler et al. / BBA Clinical 1 (2014) 12–23biologic analyses, one study investigated patients with CFS, one study
investigated ME, and one study investigated fatigue in SLE. Two of the
studies complemented medical diagnosis with a structured clinical in-
terview while one study deﬁned fatigue through the use of self-report
questionnaires.
Antioxidants (Glutathione, superoxide dismutase, catalase, GSH
peroxidase, and GSH reductase) were signiﬁcantly decreased, while
ROS and reactive nitrogen species (RNS) (malondialdehyde [MDA],
conjugated dienes, hydroperoxides, and nitric oxide) were signiﬁcantly
increased in the plasma/serum samples of CFS patients compared to
healthy controls [19]. Similar results were observed in subjects with
ME [20]. It is hypothesized that the aforementioned disruption in the
oxidative stress pathway is the downstream result of an imbalance in
intracellular calciumandmagnesium,which results in high intracellular
calcium and low intracellular magnesium [19,20].
Another study investigated the association between F2-isoprostance
levels and fatigue in patients with SLE. They observed that fatigued SLE
patients had higher levels of F2-isoprostane than non-fatigued SLE
patients [36]. A positive correlation between F2-isoprostane and fatigue
was observed in SLE patients and it was observed that F2-isoprostane
predicts higher FSS scores in SLE patients. F2-isoprostane is currently
acknowledged as the most reliable measure of in vivo oxidative stress
[36]. The results from this study provide further evidence of an associa-
tion between oxidative stress and the development of fatigue.
3.3. Mitochondrial energy metabolism
Ten studies investigated aspects ofmitochondrial energymetabolism;
all were cross-sectional in design. Most studies (n = 6) focused on fatty
acid metabolism, while the rest (n = 4) focused on ATP production.
Most studies looked at CFS or ME/CFS patients, while one study investi-
gated fatigue in MS patients.
3.3.1. ATP production
Four cross-sectional studies investigated mitochondrial energy me-
tabolism as a potential marker in fatiguing conditions. Mitochondrial
energy metabolism was assessed from muscle biopsies in two of the
studies and fromperipheral blood in the remaining studies. Two studies
only enrolled CFS patients, while the remaining two studies included
both ME and CFS patients.
The mitochondrial energy metabolism was measured using the ATP
proﬁle test in two studies [5,25]. The ATP proﬁle tests measures three
parameters of mitochondrial function in neutrophils extracted from pe-
ripheral blood, (1) ATP concentration (how much ATP is present) and
ATP ratio (what fraction of ATP is available for energy supply), (2) the
efﬁciency of oxidative phosphorylation (ADP to ATP recycling efﬁcien-
cy), and (3) TL OUT (ADP out of cytosol into mitochondria) and TL IN
(ATP from mitochondria into the cytosol). A Mitochondrial Energy
Score (MES) was calculated by multiplying all ﬁve factors (ATP, ATP
ratio, Ox Phos, TL OUT, TL IN, TL OUT × TL IN). One of the two studies
that used this ATP Proﬁle test observed that the percentage of partici-
pantswith normal values ofmitochondrial function increased as fatigue
symptoms decreased. [25]. In addition, theMES was positively correlat-
ed with scores on the CFS Ability scale [25] indicating that greater
mitochondrial efﬁciency was associated with higher levels of activity
and function in those with CFS/ME.
A second study by the same group conﬁrmed the presence of mi-
tochondrial dysfunction in patients withME/CFS by observing partial
blockage of the ADP–ATP translocator protein, adenosine nucleotide
translocase (TL) [5]. The TL protein functions to transfer ATP out of
the mitochondria into the cell cytoplasm as well as transferring
ADP from the cell cytoplasm into the mitochondria to generate
more ATP [5]. Cells can compensate for some of the dysfunction in
ATP production through two alternative pathways: by increased
glyocolysis and the use of adenlyate kinase pathway of ATPformation [5]. Therefore, partial blockage of the TL protein can lead
to impaired energy production.
Another study measured two aspects of energy metabolism in the
vastus lateralis muscle biopsy samples: aerobic respiration and respira-
tory chain function, which showed no difference between CFS patients
and healthy controls for either parameter [3]. In addition, there were
no differences in ATP production rate or respiratory chain complex
activity found in the right quadriceps muscle biopsy samples of CFS
patients compared to healthy controls [37]. Although ME/CFS patients
had impaired energy production as determined by the ATP proﬁle test,
no differences in either aerobic respiration or respiratory chain complex
activity were found in CFS patients compared to healthy controls.
3.3.2. Fatty acid metabolism
Six cross-sectional articles investigated carnitine levels in fatiguing
conditions. Five studies included CFS patients and one study included
MS patients. Four studies used peripheral blood specimens for
biologic analyses and two studies used muscle biopsies. Four studies
complimented medical diagnosis with self-report questionnaires, while
two studies assumed fatigue through medical diagnosis.
Acylcarnitine serum levels were signiﬁcantly lower in CFS patients
compared to healthy controls; however, free L-carnitine serum levels
were not signiﬁcantly different between the two groups [18]. Another
study observed signiﬁcantly lower serum levels of total and free carni-
tine in CFS patients of both genderswhen compared to healthy controls,
as well as lower serum levels of acylcarnitine in CFS patients compared
to controls, using historical data [30]. However, no difference between
total, free, and acylcarnitine serum levels were found in a more recent
study of CFS patients versus healthy controls [38], as well as in patients
with MS (with and without fatigue) compared to healthy controls [10].
Another study also showed no signiﬁcant difference in L-carnitine, total
carnitine, or total acylcarnitine plasma levels between CFS patients and
healthy controls; however, when individual acylcarnitine subtypes
were investigated in the CFS sample, 6 acylcarnitine subtypes (C8:1,
C14, C16:1, C18, C18:1 and C18:2) were signiﬁcantly lower, while 2
acylcarnitine subtypes (C12DC and C18:1-OH)were signiﬁcantly higher
in plasma of CFS participants compared to the matched controls [33].
Higher acylcarnitine serum levels were inversely correlatedwith the
Chronic Fatigue Syndrome Impairment Index (CFS-II) mental index
score and CFS-II total score [29]. Lower serum acylcarnitine was associ-
atedwithworse activity levels and symptompresentation, but these re-
lationships were not observed with free L-carnitine serum levels [18]. A
later study, however, showed that higher free carnitine serum levels
were signiﬁcantly associated with better physical abilities, and higher
free and total carnitine serum levels were signiﬁcantly associated with
lower fatigue severity [30].
4. Immune response
Four studies investigated dysfunctional immune responses to mito-
chondria in various fatiguing conditions. Three of these studies were
cross-sectional and one study used repeated measures. Three studies
only enrolled CFS patients and one study included fatigued patients
with various diagnoses. Three studies used peripheral blood specimens
for biologic analyses,while one study usedmuscle biopsies. In one study
clinical diagnosis was complemented with self-report questionnaires
and interview assessments, while three studies assumed fatigue
through medical diagnosis.
Two studies from the same research group investigated autoim-
mune responses to acute phase phospholipids in patients with fatiguing
illnesses [12,13]. CFS subjects had serum lipid fractions that resembled
those commonly found in patients poisoned with ciguatoxin, a marine
toxin [13]. Sera frompatientswith CFS, chronic ciguarteraﬁsh poisoning
(CCFP), gulf war veterans (GWV), and prostate cancer patients
contained antibodies to cardiolipin (aCL), a phospholipid of the mito-
chondrial membrane [13]. Further study found that 95% of CFS patients
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IgG response, 2.5% had an IgA response; 4 patients were positive for IgG
and IgM, and one patient was positive for all three antibody subtypes
[12].
Two studies investigated the role of enteroviral infection with the
onset of CFS [24,41]. One study examined anterior tibialis muscle biopsy
specimens for the presence of enteroviral RNA. However, they failed to
detect the presence of a persistent enteroviral infection in patients with
CFS [24]. Another study observed 23differentially expressed genes from
peripheral blood samples of patients with persistent post-Epstein–Barr
(EBV) fatigue compared to controls (those who recovered without per-
sistent fatigue) in the early phase (0–3 months) of infection. Of the 23
differentially expressed genes, 8 were found in subjects with persistent
fatigue post-EBV and were involved in binding and metabolism ontol-
ogies [41]. When exploring both early and late (N6 months) phases of
infection, 24 genes were differentially expressed between cases and
controls. Half of the 24 differentially expressed genes were associated
with mitochondrial functions such as fatty acid oxidation (CRAT,
carnitine acetyltransferase; APOA2, apolipoprotein A-II), apoptosis
(BTG1, B-cell translocation gene 1; FOLR1, folate receptor 1; CTRL,
chymotrypsin-like), DNA repair, and mitochondrial membrane
(COX8A, cytochrome c oxidase subunit VIII; COX11, cytochrome c oxi-
dase assembly protein; KCNA10, potassium voltage-gated channel;
MGP, matrix G1a protein; ATP5L, ATP synthase) [41].
In the four studies reviewed an autoimmune response was found as
evidenced by the presence ofmitochondrial phospholipids in the sera of
CFS patients. Although there was no evidence of persistent enteroviral
infection found in muscle biopsies of CFS patients, differential expres-
sion of genes associated with mitochondrial function was noted in
patients' post EBV infection. Comparing the results among these studies
is challenging. Only one research group investigated autoimmune
responses to acute phase phospholipids, publishing two different stud-
ies. Both of the studies investigating post-infective fatigue investigated
different viral infections (enterovirus vs. EBV) and the two studies
employed different study designs, cross-sectional [24] and repeated
measures [41].
5. Genetics
Five articles explored the association between gene expression
proﬁles in fatigue conditions versus controls. Three studies were
cross-sectional and two studies used repeated measures designs.
Three studies only included CFS patients, one study included men
with prostate cancer, and one study included patients with Human
Immunodeﬁciency Virus (HIV). Three studies used peripheral blood
specimens for genomic analyses, while two studies used muscle
biopsies. One study complemented clinical diagnosis with self-report
questionnaires, two studies used self-report questionnaires alone to
measure fatigue, and two assumed fatigue through medical diagnosis.
The ﬁrst genomic study found no signiﬁcant differences between
CFS patients and healthy controls in the total volume of mitochondrial
DNA present, two mtDNA rearrangements, and the presence of one
point mutation [3]. A real-time PCR (qPCR) study found 11 mitochon-
drial function-related genes to be differentially expressed during radia-
tion therapy for prostate cancer and 8 of the 11 genes were signiﬁcantly
associated with fatigue intensiﬁcation during radiation therapy [15].
These 8 genes are involved in mitochondrial apoptosis and signaling,
mitochondrial membrane polarity and potential, mitochondrial
morphology and ﬁssion/fusion, and mitochondrial and small molecule
transport [15].
One microarray analysis found 35 differentially expressed genes in
the peripheral blood mononuclear cells (PBMCs) from CFS patients,
where 3 up-regulated genes had activities speciﬁc to mitochondrial
function: EIF2B4 (eukaryotic translation initiation factor 2B, subunit
4δ, tv-1), EIF4G1 (eukaryotic translation initiation factor, 4γ, 1, tv-5),
and MRPL23 (mitochondrial ribosomal protein L23) [17]. Anothermicroarray study found 47 differentially expressed genes (2 up-
regulated and 38 down-regulated in both genders; 7 up-regulated in fe-
males, yet down-regulated in males) from vastus lateralis muscle biop-
sies of CSF patients compared to healthy controls. The down-regulated
genes were associated with an impairment of antioxidant mechanisms,
aerobic energy production, and metabolism [28]. Another study investi-
gated gene networks in CD14+ cells fromHIV-infected patients who re-
ported high fatigue, versus those who reported low fatigue or healthy
controls, where 6 mitochondrial-related genes (CHD1L and ALDOB
genes were negatively associated with fatigue; TIMM17B, GSR, IMMT,
and SLC25A26 were positively associated with fatigue) are implicated
in protein translocation into the mitochondrial matrix, cristae morphol-
ogy, ATP-binding and protein binding, metabolism, oxidation and reduc-
tion processes, and energy production were identiﬁed [42].
Five articles explored the association between gene expression pro-
ﬁles in fatiguing conditions versus controls. Common mitochondria-
speciﬁc functional pathways were reported from the results of the
gene expression studies included in review, to include pathways related
to metabolism, energy production, protein transport, mitochondrial
morphology, central nervous system dysfunction and post-viral infec-
tion. The pathways identiﬁed in these studies were similar across
three different patient populations and supported areas of dysfunction
identiﬁed in the previous sections.
6. Discussion
The purpose of this systematic review was to examine markers of
mitochondrial function that have evidence of an association with fa-
tigue in order to identify areas needed for further research. This review
included studies focusing on the markers of mitochondrial function in
relation to fatigue. Dysfunctions in the mitochondrial structure, mito-
chondrial function (mitochondrial enzymes and oxidative/nitrosative
stress), mitochondrial energy metabolism (ATP production and fatty
acid metabolism), immune response, and genetics were investigated
as potential contributors to fatigue.
Carnitine was the most investigated mitochondrial function marker
reported in this review (n = 6). Dysfunctional carnitine levels were
reported in all six studies that investigated the biomarker; however,
the speciﬁcs of the dysfunction varied among the studies. Genetic pro-
ﬁles were the second most studied mitochondrial parameter. Even
though different geneswere reported across the studies, common path-
ways (metabolism, energy production, protein transport, mitochondrial
morphology, central nervous system dysfunction, and post-viral
infection) were identiﬁed among the articles. The most commonly in-
vestigatedmitochondrial enzymewas CoQ10. It was the onlymitochon-
drial biomarker found to have a consistent association with fatigue
identiﬁed in this review [19,20,22,23]. CoQ10 is an essential enzyme
in the electron transport chain, responsible for shuttling electrons and
protons [40]. Further investigation is needed to understand the role of
CoQ10 in fatigue.
CoQ10 deﬁciency can be either primary or secondary in nature.
Primary deﬁciency stems from dysfunction with the genes coding for
the synthesis of CoQ10, whereas secondary deﬁciency results from any-
thing that is not primary in nature [14,21,31]. CoQ10 is endogenously
produced and therefore, dietary intake has minimal inﬂuence on the
CoQ10 concentration in the body. However, if CoQ10 is found to be
depleted, especially with primary deﬁciency, supplementation is the
remaining recommended therapeutic option [31]. In clinical practice,
vitamins such as riboﬂavin B2, niacin B3, vitamin E and othermitochon-
drial cofactors including levo-carnitine, lipoic acid, and acetyl-L-
carnitine are used as supplemental treatment for mitochondrial disor-
ders, in order to enhance ETC enzyme activity as an antioxidant defense
[6]. The efﬁcacy of these vitamins and mitochondrial cofactors as treat-
ments for mitochondrial disorders remains controversial [6].
CoQ10 has been shown to have clinical beneﬁts attributed to its
antioxidant properties and its role in cellular bioenergetics [21];
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mitochondria-related clinical conditions including those with cardio-
vascular disease, reproductive issues, and neurodegenerative diseases
[21]. In this review, there are only two research teams that investigated
the relationship between CoQ10 and fatigue. More clinical studies are
needed to conﬁrm the role of vitamins and mitochondrial cofactors in
alleviating fatigue symptoms [14,31].
Based on the ﬁndings of this review, alterations in energy metab-
olism may contribute to fatigue. Support for this conclusion was ev-
ident from dysfunctions reported with oxidative phosphorylation,
electron transport chain activity, and ATP production and recycling.
Impaired oxidative phosphorylation was noted through reduced cit-
rate synthase activity [24,37]. Electron transport chain activity was
disrupted as evidenced by reduced levels of succinate reductase
(Complex I), cytochrome-c oxidase (Complex IV), and CoQ10 (elec-
tron shuttle from Complex I and II to Complex III), as well as evi-
denced through disrupted oxidative stress (decreased levels of
antioxidants and increased levels of ROS and F2-isoprostance) [19,
20,22,23,24,36]. ATP concentration, recycling, and the efﬁciency of
oxidative phosphorylation were found to be disrupted through the
ATP Proﬁle Test [5,25]. Fatty acid metabolism was also impaired as
evidenced by abnormal carnitine levels [18,29,30,33]. Genetic inves-
tigations found abnormal gene transcription pathways related to
metabolism, energy production, and protein transport [15,17,28,
42]. These genetic pathways support the areas of dysfunction that
were found in the aforementioned studies.
The limitations identiﬁed in this review are: 83% of the studies
were cross-sectional, 79% of the studies enrolled only CFS patients,
and there were inconsistent associations found between mitochon-
drial biomarkers and fatigue. Future studies utilizing longitudinal
designs need to be conducted to establish associations between mi-
tochondrial dysfunction and fatigue development. Additionally, if
mitochondrial dysfunction and fatigue are observed, longitudinal
studies can provide more evidence about the characteristics of the
association.
The inclusion of diverse patient populations in future studies would
provide evidence regarding common mitochondrial mechanisms as an
etiology for fatigue. The predominant patient population included in
the reviewed studies was CFS. Knowledge gained from studies of the
CFS population needs to be translated to other fatigued populations,
such as those with cancer or other chronic diseases. Understanding
the biological mechanisms underlying fatigue development is impor-
tant to enhance clinical evaluation and treatment.
Furthermore, fatiguewas deﬁned differently among the reviewed
studies and different diagnostic criteria and self-report instruments
were used. This variability limited the ability to compare ﬁndings
across studies. Furthermore, the self-report questionnaires included
in the reviewed studies are valid measures of fatigue, but not neces-
sarily for the populations included in the studies, namely CFS. Future
research needs to work towards establishing a global agreement on
the clinical deﬁnition of fatigue. Once a clinical deﬁnition of fatigue
is established, research will need to focus on developing a valid and
reliable tool for measurement of fatigue in the clinical setting. Until
a global deﬁnition is developed, researchers need to ensure that
the existing fatigue tools are validated in their clinical populations
of interest.
The literature review identiﬁed some potential relationships be-
tween mitochondrial dysfunction and fatigue; however, the ﬁndings
were limited to predominantly one patient population, were from
mostly cross-sectional studies, and results were confounded by the
use ofmultiple deﬁnitions of fatigue. These limitations culminated in in-
consistentﬁndings across studies. Therefore, the results from the review
suggest further investigation to address the gaps in the current litera-
ture. Once the underlyingmechanisms of fatigue are better understood,
individualized and tailored therapies can be developed to improve
quality of life of patients.References
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